Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer

被引:208
作者
Vaughn, DJ
Broome, CM
Hussain, M
Gutheil, JC
Markowitz, AB
机构
[1] Univ Penn, Ctr Canc, Philadelphia, PA 19104 USA
[2] No Virginia Oncol Grp, Fairfax, VA USA
[3] Barbara Ann Karmanos Canc Inst, Detroit, MI USA
[4] Sidney Kimmel Canc Ctr, San Diego, CA USA
[5] St Joseph Reg Canc Ctr, Bryan, TX USA
关键词
D O I
10.1200/JCO.20.4.937
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: We evaluated the efficacy and toxicity of weekly paclitaxel in patients with previously treated advanced urothelial cancer. Patients and Methods: Patients with urothelial cancer who had received one prior systemic chemotherapy regimen for advanced disease and had evidence of disease progression were eligible for enrollment. Patients received paclitaxel 80 mg/m(2) by 1-hour intravenous infusion weekly. A cycle of therapy consisted of four weekly treatments. Results: The study enrolled 31 patients. Mean age was 66 years, and 45% of patients had three or more involved metastatic sites. Only 26% of patients had responded to prior chemotherapy. The median number of cycles delivered was three (range, one to eight) at a mean weekly paclitaxel dose of 79 mg/m(2). Three patients achieved a partial response (10%; 95% confidence interval, 0% to 20%). Median time to progression was 2.2 months, and median overall survival time was 7.2 months. Therapy was well tolerated with minimal hematologic toxicity. Grade 3 nonhematologic toxicities were also uncommon. Conclusion: Although the overall response rate to weekly paclitaxel in patients with previously treated advanced urothelial cancer was modest, the chemotherapy-refractory nature of the study population should be considered. (C) 2002 by American Society of Clinical Oncology.
引用
收藏
页码:937 / 940
页数:4
相关论文
共 24 条
[1]  
AbuRustum NR, 1997, SEMIN ONCOL, V24, P62
[2]   Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy [J].
Bajorin, DF ;
Dodd, PM ;
Mazumdar, M ;
Fazzari, M ;
McCaffrey, JA ;
Scher, HI ;
Herr, H ;
Higgins, G ;
Boyle, MG .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (10) :3173-3181
[3]  
BREIER S, 1998, P AN M AM SOC CLIN, V17, pA192
[4]  
Chang A Y, 1997, Semin Oncol, V24, pS17
[5]   Paclitaxel in advanced urothelial carcinoma: Its role in patients with renal insufficiency and as salvage therapy [J].
Dreicer, R ;
Gustin, DM ;
See, WA ;
Williams, RD .
JOURNAL OF UROLOGY, 1996, 156 (05) :1606-1608
[6]   Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer [J].
Fennelly, D ;
Aghajanian, C ;
Shapiro, F ;
OFlaherty, C ;
McKenzie, M ;
OConnor, C ;
Tong, W ;
Norton, L ;
Spriggs, D .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (01) :187-192
[7]  
GELLER NL, 1991, CANCER-AM CANCER SOC, V67, P1525, DOI 10.1002/1097-0142(19910315)67:6<1525::AID-CNCR2820670611>3.0.CO
[8]  
2-8
[9]   USEFULNESS AND LIMITATIONS OF METHOTREXATE, VINBLASTINE, DOXORUBICIN AND CISPLATIN FOR THE TREATMENT OF ADVANCED UROTHELIAL CANCER [J].
IGAWA, M ;
OHKUCHI, T ;
UEKI, T ;
UEDA, M ;
OKADA, K ;
USUI, T .
JOURNAL OF UROLOGY, 1990, 144 (03) :662-665
[10]   NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS [J].
KAPLAN, EL ;
MEIER, P .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) :457-481